The current state of tuberculosis vaccines

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 10, 2013, Pages 2142-2146

  Hokey, David A ^a   Ginsberg, Ann ^a  

^a AERAS   (United States)

Author keywords

BCG; Immunology; Public health; Tuberculosis; Vaccines

Indexed keywords

AERAS 422; BCG VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

CYTOKINE PRODUCTION; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG SCREENING; HOST RESISTANCE; HUMAN; IMMUNOGENICITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL;

BCG; IMMUNOLOGY; PUBLIC HEALTH; TUBERCULOSIS; VACCINES;

ANIMALS; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84885093306     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25427     Document Type: Review

References (63)

1. Global Tuberculosis Report 2012, 2012, World Health Organization: Geneva, Switzerland.
2. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med 2011;8:e1001012; PMID:21445325; http://dx.doi.org/10.1371/journal.pmed. 1001012
3. Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G. Tuberculosis and HIV co-infection. PLoS Pathog 2012;8:el002464; PMID:22363214; http://dx. doi.org/10.1371/j o urnal. ppat. 1002464
4. Falzon D, Jaramillo E, Schiinemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28; PMID:21828024; http://dx.doi.org/10.1183/09031936.00073611
5. Masjedi MR, Tabarsi P, Baghaei P, Jalali S, Farnia P, Chitsaz E, et al. Extensively drug-resistant tuberculosis treatment outcome in Iran: a case series of seven patients. Int J Infect Dis, 2010;14:e399-402; PMID: 19818664; http://dx.doi.org/l 0.1016/j. ijid.2009.07.002
6. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012;54:579-81; PMID:22190562; http://dx.doi.org/10.10 93/cid/cir 8 8 9
7. Velayati AA, Farnia P, Masjedi MR, Ibrahim TA, Tabarsi P, Haroun RZ, et al. Totally drug-resistant tuberculosis strains: evidence of adaptation at the cellular level. Eur Respir J 2009;34:1202-3; PMID: 19880622; http://dx.doi.org/10.1183/09031936.00081909
8. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drugresistant strains in iran. Chest 2009;136:420-5; PMID: 19349380; http: ZZdx. do i. o rgZ10.1378Zchest. 0 8-2427
9. Zignol M, Van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012;90:111-119D; PMID:22423162; http://dx.doi.org/10.2471/BLT11.092585
10. Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003;3:578-90; PMID: 12954564; http://dx.doi.org/10.1016/Sl473-3099 (03) 00741-2
11. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005;3:656-62; PMID: 16012514; http://dx. do i. o rg/10.103 8/nrmicro 1211
12. Barker LF, Brennan MJ, Rosenstein PK, Sadoff JC. Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol 2009;21:331-8; PMID:19505813; http://dx.doi.org/10.1016/], coi.2009.05.017
13. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993;22:1154-8; PMID:8144299; http://dx.doi.org/10.1093/ije/22.6.1154
14. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006;367:1173-80; PMID: 16616560; http://dx.doi.org/10.1016/S0l40-6736 (06) 68507-3
15. Black GF, Dockrell HM, Crampin AC, Floyd S, Weir RE, Bliss L, et al. Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi. J Infect Dis 2001;184:322-9; PMID: 11443558; http://dx.doi.org/l0.1086/322042
16. Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, Appelberg R, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002;70:672-8; PMID: 11796598; http://dx.doi. Org/10.1128/IAI.70.2.672-678.2002
17. Palmer CE, Long MW Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 1966;94:553-68; PMID: 5924215
18. Seki M, Honda I, Fujita I, Yano I, Yamamoto S, Koyama A. Whole genome sequence analysis of Mycobacterium bovis bacillus Calmette-Guerin (BCG) Tokyo 172: a comparative study of BCG vaccine substrains. Vaccine 2009;27:1710-6; PMID: 19200449; http://dx.doi. Org/10.1016/j.vaccine.2009.01.034
19. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 2010;375:2110-9; PMID:20488515; http://dx.doi.org/10.1016/S0l40-6736 (10) 60393-5
20. Cisneros JR, Murray KM. Corticosteroids in tuberculosis. Ann Pharmacother 1996;30:1298-303; PMID:8913413
21. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 2001;345:1098-104; PMID:11596589; http://dx.doi.org/10.1056/NEJMoa011110
22. Nunez Martfnez O, Ripoll Noiseux C, Carneros Martfn JA, Gonzalez Lara V, Gregorio Maranon HG. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol 2001;96:1665-6; PMID: 11374737
23. Hernandez-Pando R, Aguilar D, Hernandez ML, Orozco H, Rook G. Pulmonary tuberculosis in BALB/c mice with non-functional IL-4 genes: changes in the inflammatory effects of TNF-alpha and in the regulation of fibrosis. Eur J Immunol 2004;34:174-83; PMID: 14971043; http://dx.doi.org/10.1002/eji.200324253
24. Rook GA, Hernandez-Pando R, Dheda K, Teng Seah G. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 2004;25:483-8; PMID: 15324741; http://dx.doi. Org/10.1016/j.it.2004.06.005
25. Hokey DA, Misra A. Aerosol vaccines for tuberculosis: a fine line between protection and pathology. Tuberculosis (Edinb) 2011;91:82-5; PMID:21067975; http://dx.doi. Org/10.1016/j.tube.2010.09.007
26. Elias D, Akuffo H, Britton S. PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 2005;99:363-8; PMID: 15780343; http:ZZdx.doi.orgZl0.1016Zj.trstmh.2004.08.006
27. Theron G, Peter J, Lenders L, Van Zyl-Smit R, Meldau R, Govender U, et al. Correlation of mycobacterium tuberculosis specific and non-specific quantitative Thl T-cell responses with bacillary load in a high burden setting. PLoS One 2012;7:e37436; PMID:22629395; http://dx.doi.org/10.1371/jo urnal. pone.0037436
28. Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998;280:1432-5; PMID:9603732; http://dx. doi.org/10.1126/science.280.5 368.1432
29. De Jong R, Altare F, Haagen IA, Elferink DG, Boer T, Van Breda Vriesman PJ, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998;280:1435-8; PMID:9603733; http://dx.doi.org/10.1126/science.280.5368.1435
30. Jouanguy E, Doffenger R, Dupuis S, Pallier A, Altare F, Casanova JL. IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. Curr Opin Immunol 1999;11:346-51; PMID: 10375558; http://dx.doi.org/10. 1016/S0952-7915 (99) 80055-7
31. Lammas DA, Casanova JL, Kumararatne DS. Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-gamma) pathway. Clin Exp Immunol 2000;121:417-25; PMID:10971505; http://dx.doi.org/10.1046/j. 1365-2249.2000.01284.x
32. Chaisson RE, Martinson NA. Tuberculosis in Africa-combating an HIV-driven crisis. N Engl J Med 2008;358:1089-92; PMID:18337598; http://dx.doi.org/10. 1056/NEJMP0800809
33. Pacheco AG, Durovni B, Cavalcante SC, Lauria LM, Moore RD, Moulton LH, et al. AIDS-related tuberculosis in Rio de Janeiro, Brazil. PLoS One 2008;3:e3132; PMID: 18781195; http://dx.doi.org/10.1371/journal.pone.0003132
34. Wangoo A, Sparer T, Brown IN, Snewin VA, Janssen R, Thole J, et al. Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol 2001;166:3432-9; PMID:11207301
35. Chen CY, Huang D, Wang RC, Shen L, Zeng G, Yao S, et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog 2009;5:e1000392; PMID: 19381260; http://dx.doi.org/10.13711) o urnal. ppat.1000392
36. Davids V, Hanekom W, Gelderbloem SJ, Hawkridge A, Hussey G, Sheperd R, et al. Dose-dependent immune response to Mycobacterium bovis BCG vaccination in neonates. Clin Vaccine Immunol 2007;14:198-200; PMID: 17182761; http://dx.doi.org/10.1128/CVI.00309-06
37. Rook GA, Dheda K, Zumla A. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th 1-b oosting? Vaccine 2005;23:2115-20; PMID:15755581; http:ZZdx.doi.orgZl0.1016Zj.vaccine.2005.01.069
38. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008;198:544-52; PMID: 18582195; http://dx.doi.org/1 0.1086/590185
39. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004;10:1240-4; PMID: 15502839; http://dx.doi.org/10.1038/nmll28
40. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003;171:1602-9; PMID: 12874255
41. Williams A, Goonetilleke NP, McShane H, Clark SO, Hatch G, Gilbert SC, et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun 2005;73:3814-6; PMID: 15908420; http://dx.doi.org/10.1128/IAI.73.6.3814-3816.2005
42. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al.; MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infante previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381:1021-8; PMID:23391465; http://dx.doi.org/10.1016/SO 140-6736(13)60177-4
43. Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, Penn E, et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009;27:4412-23; PMID: 19500523; http://dx.doi.org/10.1016Zj.vaccine.2009.05.048
44. Graves AJ, Hokey DA. Tuberculosis Vaccines: Review of Current Development Trends and Future Challenges. Bioterrorism & Biodefense, 2011.
45. Velmurugan K, Grode L, Chang R, Fitzpatrick M, Laddy D, Hokey D, et al. Nonclinical Development of BCG Replacement Vaccine Candidates. Vaccines 2013;2013:120-38; http://dx.doi.org/10.3390/vaccinesl 020120
46. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 2012;8:e1002607; PMID:22589713; http://dx.doi.org/10.1371/journal.ppat.1002607
47. Hoft DF, Blazevic A, Selimovic A, Turan A, Tennant J, Abate G, et al. S6 Safety Signal Associated with Recombinant BCG Vaccination: Immunologic Clue or Chance Occurrence? in NFID 2012 Fifteenth Annual Conference on Vaccine Research. 2012.
48. Cowan J, Pandey S, Filion LG, Angel JB, Kumar A, Cameron DW. Comparison of interferon-γ-, interleukin (IL)-17-and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection. Clin Exp Immunol 2012;167:317-29; PMID:22236009; http://dx.doi. Org/10.1111/j.1365-2249.2011.04520.x
49. Curtis MM, Way SS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 2009;126:177-85; PMID:19125888; http://dx.doi. Org/10.1111/j.1365-2567.2008.03017.x
50. Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F. Regulation of interleukin-12/interleukin-2 3 production and the T-helper 17 response in humans. Immunol Rev 2008;226:112-31; PMID: 19161420; http://dx.doi. Org/10.1111/j.1600-065X.2008.00700.x
51. Zeng G, Chen CY, Huang D, Yao S, Wang RC, Chen ZW Membrane-bound IL-22 after de novo production in tuberculosis and anti-Mycobacterium tuberculosis effector function of IL-22+ CD4+ T cells. J Immunol 2011;187:190-9; PMID:21632708; http://dx.doi.org/10.4049/j immunol. 1004129
52. Maglione PJ, Chan J. How B cells shape the immune response against Mycobacterium tuberculosis. Eur J Immunol 2009;39:676-86; PMID: 19283721; http://dx.doi.org/10.1002/eji.200839148
53. Achkar JM, Casadevall A. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 2013;13:250-62; PMID:23498951; http://dx.doi.org/l 0.1016/j. chom.2013.02.009
54. Boyer JD, Robinson TM, Kutzler MA, Vansant G, Hokey DA, Kumar S, et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A 2007;104:18648-53; PMID: 18000037; http://dx.doi.org/10.1073/pnas.0709198104
55. Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008;26:3112-20; PMID: 18430495; http://dx.doi.org/10.1016/j. vaccine.2008.02.036
56. Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, Fries L, et al. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis 1997;175:915-20; PMID: 9086149; http://dx.doi.org/10.1086/513990
57. Miller FG, Grady C. The ethical challenge of infection-inducing challenge experiments. Clin Infect Dis 2001;33:1028-33; PMID:11528576; http://dx.doi.org/10.1086/322664
58. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011;11:57-64; PMID:21179119; http://dx.doi.org/10.1038/nri2902
59. Minassian AM, Ronan EO, Poyntz H, Hill AV, McShane H. Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy. PLoS One 2011;6:e19840; PMID:21629699; http://dx.doi.org/10.1371/jo urnal. pone.0019840
60. Minassian AM, Satti I, Poulton ID, Meyer J, Hill AV, McShane H. A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. J Infect Dis 2012;205:1035-42; PMID:22396610; http://dx.doi.org/10.109 3/infdis/j is 012
61. Riley RL, Mills CC, Nyka W, Weinstock N, Storey PB, Sultan LU, et al. Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959. Am J Epidemiol 1995;142:3-14; PMID:7785671
62. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 2009;77:4631-42; PMID: 19620341; http://dx.doi.org/l 0.1128/IAI. 00592-09
63. Knight G. Global cost-effectiveness of new tuberculosis vaccines: A modelling study, in TB Vaccines Third Global Forum. 2013. Cape Town, South Africa.